IQVIA Holdings Inc. $IQV Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 338,340 shares of the medical research company’s stock after selling 26,119 shares during the quarter. Hsbc Holdings PLC owned 0.20% of IQVIA worth $76,303,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IQV. Boston Partners acquired a new stake in shares of IQVIA in the 3rd quarter valued at $676,698,000. Norges Bank acquired a new position in shares of IQVIA during the fourth quarter worth $497,445,000. Victory Capital Management Inc. increased its holdings in IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after buying an additional 1,614,063 shares during the last quarter. Orbis Allan Gray Ltd raised its stake in IQVIA by 96.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after buying an additional 933,554 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after buying an additional 879,701 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of IQV opened at $167.83 on Tuesday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock’s 50 day moving average is $173.60 and its two-hundred day moving average is $191.01. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04. The firm has a market capitalization of $28.01 billion, a PE ratio of 20.80, a P/E/G ratio of 1.44 and a beta of 1.21.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the previous year, the firm earned $2.70 EPS. The business’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a stock repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on IQV shares. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a report on Friday, March 6th. HSBC set a $210.00 target price on IQVIA in a research report on Wednesday, June 3rd. Evercore reissued an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Finally, TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and raised their price target for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $222.56.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.